Recursion Pharmaceuticals (RXRX) Accounts Payables (2020 - 2026)

Recursion Pharmaceuticals' Accounts Payables history runs 7 years deep, the most recent figure standing at $20.3 million for Q1 2026.

• Quarterly Accounts Payables fell 18.89% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 18.89% YoY) and the FY2025 annual result came in at $18.1 million, down 16.17% from the prior year.
• Accounts Payables was $20.3 million for Q1 2026 at Recursion Pharmaceuticals, up from $18.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $25.1 million in Q1 2025 and bottomed at $2.1 million in Q2 2023.
• A 5-year average of $9.4 million and a median of $4.3 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables tumbled 47.01% — and 2025, when it soared 516.59%.
• Recursion Pharmaceuticals' Accounts Payables stood at $4.6 million in 2022, then dropped by 13.8% to $4.0 million in 2023, then soared by 446.75% to $21.6 million in 2024, then slipped by 16.17% to $18.1 million in 2025, then gained by 12.31% to $20.3 million in 2026.
• Business Quant data shows RXRX's Accounts Payables at $20.3 million in Q1 2026, $18.1 million in Q4 2025, and $13.9 million in Q3 2025.